Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATRA NASDAQ:AVRO NASDAQ:NITE OTCMKTS:OSIR NASDAQ:PRTO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$9.27+8.0%$7.85$5.01▼$18.71$51.15M0.18117,786 shs41,364 shsAVROAVROBIO$9.98$0.88▼$1.65$62.85M1.23269,831 shs206,800 shsNITENightstar Therapeutics$31.01+0.0%$25.41$9.59▼$29.55$1.04B2.84185,808 shs1,131 shsOSIROsiris Therapeutics$18.99$18.99$7.01▼$19.30$655.69MN/A205,753 shsN/APRTOProteon Therapeutics$2.80-3.1%$19.37$0.22▼$3.94$62.10M0.61.11 million shs341,538 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics+8.04%+18.85%+0.43%+57.39%+16.46%AVROAVROBIO0.00%0.00%0.00%0.00%0.00%NITENightstar Therapeutics-1.46%+0.56%+5.57%+38.23%+16.98%OSIROsiris Therapeutics0.00%0.00%0.00%0.00%0.00%PRTOProteon Therapeutics-3.11%-7.59%-16.04%-25.33%+35.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATRAAtara Biotherapeutics4.0952 of 5 stars3.33.00.04.70.62.50.6AVROAVROBION/AN/AN/AN/AN/AN/AN/AN/ANITENightstar TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOSIROsiris TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APRTOProteon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics 2.57Moderate Buy$17.7591.48% UpsideAVROAVROBIO 0.00N/AN/AN/ANITENightstar Therapeutics 0.00N/AN/AN/AOSIROsiris Therapeutics 0.00N/AN/AN/APRTOProteon Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$128.94M0.43N/AN/A($16.89) per share-0.55AVROAVROBION/AN/AN/AN/A$2.13 per shareN/ANITENightstar TherapeuticsN/AN/AN/AN/A$5.89 per shareN/AOSIROsiris TherapeuticsN/AN/AN/AN/AN/AN/APRTOProteon TherapeuticsN/AN/AN/AN/A($0.06) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics-$85.40M-$3.72N/AN/AN/A-7.83%N/A-14.51%8/11/2025 (Estimated)AVROAVROBIO$12.16M$0.692.03N/AN/AN/A-50.52%-47.13%N/ANITENightstar Therapeutics-$36.86M-$1.26N/AN/AN/AN/A-30.89%-27.65%N/AOSIROsiris TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/APRTOProteon Therapeutics-$20.73M-$1.15N/AN/AN/AN/AN/A-118.68%N/ALatest NITE, PRTO, ATRA, AVRO, and OSIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ATRAAtara Biotherapeutics-$3.07$3.50+$6.57$3.50$4.30 million$98.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/AAVROAVROBION/AN/AN/AN/AN/ANITENightstar TherapeuticsN/AN/AN/AN/AN/AOSIROsiris TherapeuticsN/AN/AN/AN/AN/APRTOProteon TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A0.570.57AVROAVROBION/A26.1726.17NITENightstar TherapeuticsN/A8.548.54OSIROsiris TherapeuticsN/AN/AN/APRTOProteon TherapeuticsN/A5.985.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%AVROAVROBIO62.63%NITENightstar Therapeutics32.83%OSIROsiris Therapeutics0.28%PRTOProteon Therapeutics23.03%Insider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics4.00%AVROAVROBIO9.20%NITENightstar TherapeuticsN/AOSIROsiris Therapeutics43.40%PRTOProteon Therapeutics45.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics3305.96 million5.72 millionOptionableAVROAVROBIO1344.89 million40.76 millionOptionableNITENightstar Therapeutics4733.54 millionN/ANot OptionableOSIROsiris Therapeutics34234.53 millionN/ANot OptionablePRTOProteon Therapeutics1722.18 millionN/ANot OptionableNITE, PRTO, ATRA, AVRO, and OSIR HeadlinesRecent News About These CompaniesProQR Therapeutics price target raised to $4 from $2.50 at ChardanNovember 9, 2024 | markets.businessinsider.comProtara Therapeutics (TARA) Earnings Dates & ReportsNovember 1, 2024 | investing.comProQR Therapeutics upgraded to Strong Buy from Outperform at Raymond JamesOctober 29, 2024 | markets.businessinsider.comPROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On MondayOctober 28, 2024 | msn.comProQR Announces Major Share Offering AgreementOctober 25, 2024 | markets.businessinsider.comSeaport raises $225m to advance portfolio of neuropsychiatric prodrugsOctober 22, 2024 | msn.comUnderstanding Neurodegenerative Disease with Prion ResearchSeptember 13, 2024 | the-scientist.comTProdrugs and patents: Enhancing therapy adherence and reducing side effectsSeptember 11, 2024 | msn.comiPhone 13 Pro vs. iPhone 16 Pro: 65+ Upgrades to ExpectSeptember 8, 2024 | macrumors.comMPS5 Pro: the latest on rumored specs, price, and release date speculationAugust 30, 2024 | techradar.comTRapport Therapeutics Seeks IPO For CNS Treatment ProgramsMay 22, 2024 | seekingalpha.comPTC Therapeutics: Q1 Earnings SnapshotApril 25, 2024 | timesunion.comTProtara Therapeutics Inc (TARA)April 24, 2024 | investing.comiPad ProFebruary 2, 2024 | macrumors.comMEsperion Therapeutics Inc ESPRNovember 5, 2023 | morningstar.comMThe Latest Analyst Ratings for Revance TherapeuticsSeptember 20, 2023 | benzinga.comENLV - Enlivex Therapeutics Ltd.June 6, 2023 | finance.yahoo.comPrelude Therapeutics Insider Trades Send a SignalMay 25, 2023 | benzinga.comGlobal Protein Therapeutics Market Report 2023: Development of Plasma Derived Therapies Drives GrowthMay 22, 2023 | benzinga.comThe best iPhone 14 Pro deals for May 2023May 18, 2023 | techradar.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesTop Steel Picks for the Coming Infrastructure BoomBy Chris Markoch | June 25, 2025View Top Steel Picks for the Coming Infrastructure BoomUnitedHealth Stock Dips: Is This a Value Buy Opportunity?By Jeffrey Neal Johnson | June 13, 2025View UnitedHealth Stock Dips: Is This a Value Buy Opportunity?UPS Is Outpacing the Market: A Green Light for Investors?By Jeffrey Neal Johnson | June 27, 2025View UPS Is Outpacing the Market: A Green Light for Investors?Micron Joins Latest $200 Billion United States Investment By Gabriel Osorio-Mazilli | June 16, 2025View Micron Joins Latest $200 Billion United States Investment Reddit Stock Ignites: Surge in Call Options Signals Big BetBy Gabriel Osorio-Mazilli | June 24, 2025View Reddit Stock Ignites: Surge in Call Options Signals Big BetNITE, PRTO, ATRA, AVRO, and OSIR Company DescriptionsAtara Biotherapeutics NASDAQ:ATRA$9.27 +0.69 (+8.04%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$9.24 -0.03 (-0.32%) As of 07/8/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.AVROBIO NASDAQ:AVROAVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Nightstar Therapeutics NASDAQ:NITENightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. In addition, the company is developing NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. The company was founded in 2013 and is headquartered in London, the United Kingdom.Osiris Therapeutics OTCMKTS:OSIR$18.99 0.00 (0.00%) As of 04/17/2019Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.Proteon Therapeutics NASDAQ:PRTOProteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.